Drug Trial Radar · NCT05254002
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,664
Actual
Start
Jun 23, 2022
Primary completion
Mar 14, 2025
Study completion Mar 17, 2025
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Feb 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD. Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine. In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the participants' kidney function compared to either treatment alone. For this, the level of protein in the urine will be measured. The investigators also want to know how safe the combination is compared to either treatment alone. Depending on the treatment group, the participants will either take the combination of finerenone and empagliflozin, or finerenone together with a placebo, or empagliflozin together with a placebo, once a day as tablets by mouth. A placebo looks like a treatment but does not have any medicine in it. Importantly, the participants will also continue to take their other current medicine for CKD and T2D. The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, participants will visit the study site 7 times. The study team will: * collect blood and urine samples * check the participants' vital signs * do a physical examination including height and weight * check the participants' heart health by using an electrocardiogram (ECG) * monitor the participants' blood pressure * ask the participants questions about how they are feeling and what adverse events they may be having An adverse event is any problem that happens during the trial. Doctors keep track of all events that happen in trials, even if they do not think the events might be related to the study treatments.
Conditions
- Type 2 Diabetes Mellitus
- Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862 ) 10 mgDrug
oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2
EmpagliflozinDrug
oral administration, once daily
Empagliflozin PlaceboDrug
Matching placebo to empagliflozin oral administration, once daily
Finerenone (BAY94-8862 ) 20 mgDrug
oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2
Finerenone PlaceboDrug
Matching Placebo to Finerenone oral administration once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Empagliflozin AloneTime frame: Baseline and Day 180
- Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Finerenone AloneTime frame: Baseline and Day 180
Locations
173 sites in 14 countries. Site status is shown where the registry gives one.
Southwest Kidney Institute, PLC - Suprise
Surprise, Arizona
Academic Medical Research Institute
Los Angeles, California
Dignity Health Northridge Hospital Medical Center - Nephrology
Northridge, California
Olive View - UCLA Medical Center
Sylmar, California
Touro University California - Metabolic Research Center
Vallejo, California
Florida Kidney Physicians - Delray Beach Nephrology
Delray Beach, Florida
West Orange Endocrinology & Clinical Research
Ocoee, Florida
Innovative Research Institute
Port Charlotte, Florida
Metabolic Research Institute, Inc.
West Palm Beach, Florida
Grady Memorial Hospital - Endocrinology
Atlanta, Georgia
Southeast Kidney Associates - East Point
East Point, Georgia
Velocity Clinical Research - Savannah
Savannah, Georgia
Nola Care Clinical Research
Metairie, Louisiana
Omega Clinical Research - Metairie
Metairie, Louisiana
South Shore Nephrology
Plymouth, Massachusetts
Lake Michigan Nephrology
Saint Joseph, Michigan
Oakland Medical Research
Troy, Michigan
Clinical Research Consultants, a JCCT Company
Kansas City, Missouri
Kansas City VA Medical Center - Endocrinology
Kansas City, Missouri
Center for Advanced Medicine - Diabetes Center
St Louis, Missouri
St. Louis Heart and Vascular, PC - Christian Hospital Office
St Louis, Missouri
Somnos Clinical Research
Lincoln, Nebraska
Healor Primary Care / CCT Research
Las Vegas, Nevada
CCT Research - Santa Rosa Medical Centers of Nevada
Las Vegas, Nevada
Circuit Clinical/Crystal Run
Middletown, New York
Randolph Health Internal Medicine in Asheboro
Asheboro, North Carolina
UNC Hospitals Outpatient Center at Eastowne - Nephrology
Chapel Hill, North Carolina
Eastern Nephrology Associates - Greenville West
Greenville, North Carolina
Blue Sky, MD/ Lamond Family Medicine
Hendersonville, North Carolina
Eastern Nephrology Associates - Kinston
Kinston, North Carolina
Velocity Clinical Research - Blue Ash
Cincinnati, Ohio
Dunes Clinical Research LLC
Dakota Dunes, South Dakota
DarSalud Care / LifeDOC Research
Memphis, Tennessee
The University of Tennessee Health Science Center - Medical Center Clinic - Nephrology
Memphis, Tennessee
Office of Osvaldo A. Brusco, MD
Corpus Christi, Texas
Thyroid, Endocrinology, and Diabetes - Dallas
Dallas, Texas
DaVita Clinical Research- El Paso
El Paso, Texas
Global Kidney Center
Houston, Texas
Victorium Clinical Research
Houston, Texas
North Texas Kidney Disease Associates Lewisville
Lewisville, Texas
Showing 40 of 173 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.